Global Pharmatech Private Limited

Global Pharmatech Private Limited, established on February 5, 1993, is a privately held Indian pharmaceutical company headquartered in Bangalore, Karnataka. The company is registered under the Corporate Identification Number (CIN) U24231KA1993PTC013976. As of the latest available data, Global Pharmatech has an authorized capital of ₹155.3 million and a paid-up capital of ₹146.935 million. The company's principal business activity falls under the category of 'Community, personal & Social Services.'

The registered office is located at IBC Knowledge Park, Phase 2, D Block, 9th Floor, 4/1, Bannerghatta Road, Bangalore, Karnataka 560029, India. The company is unlisted and has been operational for over three decades, focusing on the export of finished pharmaceutical formulations.

Global Pharmatech operates a manufacturing facility in Hosur, Tamil Nadu, which specializes in the production of high-quality liquid sterile formulations. The facility is capable of manufacturing both aseptically filled and terminally sterilized products, including small volume glass vials, ampoules, and large volume glass bottles. This plant is equipped to handle end-to-end pharmaceutical development and manufacturing processes, ranging from formulation development to global regulatory management.

The leadership team of Global Pharmatech Private Limited includes:

• Anna Thomas Chacko: Director
• Bipin Ratilal Shah: Director
• Thomas Thomas: Director
• Arumugam Bhaskar Krishna: Director
• Sylvain Duvernay: Director

These individuals have been associated with the company since their respective appointments, contributing to its strategic direction and operational success.

Global Pharmatech Private Limited has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facility in Hosur, Tamil Nadu, holds certifications such as US FDA, EU GMP, Health Canada, and PIC/S, indicating compliance with international regulatory standards. These certifications facilitate the company's market access and product acceptance in these regions.

In addition to its presence in regulated markets, Global Pharmatech Private Limited has expanded its reach to emerging markets in Africa, Latin America, and Southeast Asia. The company's WHO prequalification enables it to supply pharmaceutical products to these regions, enhancing access to quality medicines. This strategic expansion aligns with the company's mission to improve global health outcomes through affordable and reliable pharmaceutical solutions.

Global Pharmatech's geographic strategy demonstrates a balanced approach, with a significant portion of its exports directed towards the cardiovascular therapeutic category (65.0%) and the respiratory & OTC category (35.0%). This diversification mitigates concentration risk and positions the company to leverage opportunities across different therapeutic areas. The strategic direction focuses on expanding market presence while maintaining a diversified product portfolio to cater to a broad spectrum of patient needs.

The manufacturing facility of Global Pharmatech Private Limited in Hosur, Tamil Nadu, is registered with the US Food and Drug Administration (FDA). The facility has undergone FDA inspections, with the most recent Form 483 issued on August 2, 2019, indicating areas for improvement. The company has taken corrective actions to address the observations, demonstrating a commitment to compliance and quality standards.

Global Pharmatech Private Limited's manufacturing facility holds certifications from the World Health Organization (WHO) and the European Union Good Manufacturing Practice (EU GMP). These certifications affirm the company's adherence to international quality standards, ensuring the safety and efficacy of its pharmaceutical products. Such certifications are crucial for market acceptance and regulatory approvals in various global markets.

In India, Global Pharmatech Private Limited operates under the guidelines set by the Central Drugs Standard Control Organisation (CDSCO). The company's manufacturing facility in Hosur, Tamil Nadu, holds the necessary manufacturing licenses and approvals from state drug controllers, ensuring compliance with national regulatory requirements. Additionally, the company has obtained export No Objection Certificates (NOCs), facilitating the export of its pharmaceutical products to international markets.

The manufacturing facility of Global Pharmatech Private Limited in Hosur, Tamil Nadu, received a Form 483 from the US FDA on August 2, 2019. This document highlighted specific observations regarding the facility's compliance with FDA regulations. The company has since implemented corrective measures to address these observations, reflecting its commitment to maintaining high-quality manufacturing standards.

In the cardiovascular therapeutic category, Global Pharmatech Private Limited's product, Diltiazem, holds a market share of 3.6%, ranking 6th in the market. In the respiratory & OTC category, the company's product, Ephedrine, holds a market share of 1.6%, ranking 11th. These positions indicate a competitive presence in these therapeutic areas, with opportunities for growth through strategic initiatives and market expansion.

Global Pharmatech Private Limited's key differentiators include its extensive experience in manufacturing high-quality liquid sterile formulations and its commitment to compliance with international regulatory standards. The company's WHO prequalification and EU GMP certifications enhance its credibility and marketability in global markets. Additionally, the company's diversified product portfolio across cardiovascular and respiratory & OTC categories allows it to cater to a broad spectrum of patient needs.

Global Pharmatech Private Limited's current strategic direction focuses on expanding its presence in both regulated and emerging markets, leveraging its manufacturing capabilities and regulatory certifications. The company's future outlook includes enhancing its product portfolio, strengthening its market position, and exploring opportunities in generics, specialty pharmaceuticals, and contract development and manufacturing organizations (CDMO) services. This strategic approach aims to drive sustainable growth and deliver value to stakeholders.

Global Pharmatech Private Limited has demonstrated a consistent track record in pharmaceutical manufacturing, with a total export value of $1.0 million USD across 20 shipments. The company's portfolio concentration is notable, with its top 5 products accounting for 100% of its exports. This indicates a focused approach to product offerings, which can be advantageous in maintaining quality and operational efficiency. The company's adherence to international quality standards and regulatory certifications further underscores its reliability as a supplier.

Importers should verify the following certifications when considering Global Pharmatech Private Limited as a supplier:

• FDA Registration: Confirm the facility's registration status with the US FDA to ensure compliance with US regulations.
• WHO-GMP Certification: Verify the facility's certification from the World Health Organization to ensure adherence to international quality standards.
• EU GMP Certification: Check for certification from the European Union to confirm compliance with European manufacturing standards.
• ISO Certifications: Ensure the facility holds relevant ISO certifications, such as ISO 9001:2015, to assess quality management systems.

These certifications can typically be verified through the respective regulatory bodies' official websites or by requesting documentation directly from the supplier.

When conducting due diligence on Global Pharmatech Private Limited, consider the following steps:

• Regulatory Compliance: Review the company's certifications and regulatory approvals to ensure compliance with international standards.
• Quality Assurance: Assess the company's quality management systems and any history of regulatory observations or corrective actions.
• Financial Stability: Evaluate the company's financial statements to assess its financial health and operational efficiency.
• Supply Chain Reliability: Investigate the company's supply chain practices to ensure consistent product availability and delivery timelines.
• References and Reviews: Seek feedback from existing clients or partners to gauge the company's reputation and reliability.

Red flags to watch for include unresolved regulatory issues, financial inconsistencies, and negative feedback from business partners. Recommended pre-order checks involve verifying product quality through samples, assessing compliance with import regulations, and confirming the company's ability to meet delivery schedules.